Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance and guidelines

A list of downloadable documents created during development.

Background information

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review decision - April 2015 information

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: appendix A - GE decision paper - April 2015 27 April 2015 120.27 KB

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: review proposal - April 2014 information

Appendix A - provisional matrix of stakeholders 23 April 2014 97.94 KB

Appendix B - proposal paper presented to the Institute's Guidance Executive 23 April 2014 873.38 KB

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: press release information

2011/047 NICE guidance extends recommendations on Alzheimer's drugs 06 December 2013 89.17 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development 29 March 2011 74.21 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination information

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination 18 January 2011 362.15 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response to comments on the appraisal consultation 18 January 2011 470.71 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the appraisal consultation

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Eisai/Pfizer 18 January 2011 53.01 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Lundbeck 18 January 2011 127.47 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the executable model from Lundbeck 18 January 2011 16.35 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Novartis 18 January 2011 85.48 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Shire 18 January 2011 57.03 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Alzheimer's Society 18 January 2011 97.45 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Association of British Neurologists 18 January 2011 149.81 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from British Geriatrics Society 18 January 2011 87.8 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Nursing 18 January 2011 66.18 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comment on the appraisal consultation from Royal College of Psychiatrists 18 January 2011 124.89 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert comment on the appraisal consultation from Dr Peter Connelly 17 January 2011 42.32 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments on the ACD received through the NICE website 18 January 2011 247.4 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation document information

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): evaluation report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model A 07 October 2010 4.31 MB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): a systematic review and economic model B 07 October 2010 2.18 MB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): additional analysis for PenTAG 07 January 2010 34.83 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAG new results 07 October 2010 1.29 MB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): PenTAGs parameters in the Lundbeck model 07 October 2010 49.79 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): consultee and commentator comments on the assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from the Research Institute for the Care of Older People 07 October 2010 80.82 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Shire 07 October 2010 84.85 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Novartis 07 October 2010 103.64 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS Quality Improvement Scotland 07 October 2010 129.12 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from NHS West Kent 07 October 2010 67.89 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): commments from the Alzheimer's Society 07 October 2010 172.59 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): comments from Eisai Ltd/Pfizer Ltd (joint response) 07 October 2010 583.29 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck 07 October 2010 872.83 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): non-manufacturer submission

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Alzheimer's Society (part 1) 07 October 2010 371.99 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): British Geriatrics Society 07 October 2010 159.99 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Royal College of Psychiatrists 07 October 2010 211.75 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): manufacturer full submissions

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Eisai Ltd/Pfizer Ltd (joint submission) 07 October 2010 924.29 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Lundbeck UK 07 October 2010 998.77 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Shire Pharmaceuticals 07 October 2010 134.41 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): response from Peninsula Technology Assessment Group (PenTAG) 07 October 2010 290.42 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): expert written personal statements

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Connelly 07 October 2010 123.32 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Hill 07 October 2010 53.62 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): Simmons 07 October 2010 62.23 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): overview 07 October 2010 611.9 KB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 1) 14 July 2010 4.31 MB

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report (part 2) 14 July 2010 2.15 MB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol 20 January 2010 111.79 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix 07 December 2009 30.36 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope 20 November 2009 45.87 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix 20 November 2009 29.81 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope 20 November 2009 231.5 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix 24 September 2009 29.98 KB

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope

Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope 24 September 2009 50.32 KB